Changes in metformin use in chronic kidney disease

Imam, Talha H

doi:10.1093/ckj/sfx017

Cited by 20 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, AMPK could provide a potential approach to alleviate diabetic renal damage [45]. Metformin, an indirect activator of AMPK has been confirmed to improve renal function by downregulating the expression of renal fibrotic proteins [46, 47], which is in accordance with our previous animal experiment. In the present study, AC and marein promoted AMPK activation thereby preventing renal dysfunction.…”

Section: Discussionsupporting

confidence: 77%

Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways

Yao

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundCoreopsis tinctoria Nutt is an ethnomedicine widely used in Xinjiang, China. It is consumed as a herbal tea by local Uyghur people to treat high blood pressure and diarrhea. Our previous study confirmed that the ethyl acetate extract of Coreopsis tinctoria (AC) had a protective effect on diabetic nephropathy (DN) in an in vivo experiment. Here we aim to elucidate the protective mechanism of AC and marein, the main ingredient in Coreopsis tinctoria on renal fibrosis and inflammation in vitro under high glucose (HG) conditions.MethodsA HG-induced barrier dysfunction model in rat mesangial cells (HBZY-1) was established. The cells were exposed to AC and marein and/or HG for 24 h. Then, the renal protective effects of AC and marein via transforming growth factor-β1 (TGF-β1)/Smads, AMP-activated kinase protein (AMPK), and nuclear factor kappa beta (NF-κB) signaling were assessed.ResultsBoth AC and marein suppressed rat mesangial cell hyperplasia and significantly attenuated the expression of HG-disrupted fibrotic and inflammatory proteins in HBZY-1 cells. It was also confirmed that AC and marein remarkably attenuated HG-induced renal inflammation and fibrosis by regulating the AMPK, TGF-β1/Smads, and NF-κB signaling pathways.ConclusionThese results indicated that AC and marein may delay the progression of DN, at least in part, by suppressing HG-induced renal inflammation and fibrosis. Marein may be one of the bioactive compounds in AC.

show abstract

Section: Discussionsupporting

confidence: 77%

Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways

Yao

et al. 2019

BMC Complement Altern Med

View full text Add to dashboard Cite

show abstract

“…Metformin is widely accepted as the first-line therapy of type 2 diabetes mellitus (T2DM), because of its capacity to lower blood glucose in association with beneficial effects on plasma lipids, body weight, and a low incidence of micro- and macrovascular events [1,2]. It is one of the oldest and most prescribed antidiabetic drugs worldwide [3]. Historically, metformin originates from galegine, a guanidine derivative found in Galega officinalis , and was used in herbal medicine in medieval Europe [2,4].…”

Section: Introductionmentioning

confidence: 99%

Metformin: A Candidate Drug for Renal Diseases

Corremans

Vervaet

D’Haese

et al. 2018

IJMS

View full text Add to dashboard Cite

Over the past decades metformin has been the optimal first-line treatment for type 2 diabetes mellitus (T2DM). Only in the last few years, it has become increasingly clear that metformin exerts benign pleiotropic actions beyond its prescribed use and ongoing investigations focus on a putative beneficial impact of metformin on the kidney. Both acute kidney injury (AKI) and chronic kidney disease (CKD), two major renal health issues, often result in the need for renal replacement therapy (dialysis or transplantation) with a high socio-economic impact for the patients. Unfortunately, to date, effective treatment directly targeting the kidney is lacking. Metformin has been shown to exert beneficial effects on the kidney in various clinical trials and experimental studies performed in divergent rodent models representing different types of renal diseases going from AKI to CKD. Despite growing evidence on metformin as a candidate drug for renal diseases, in-depth research is imperative to unravel the molecular signaling pathways responsible for metformin’s renoprotective actions. This review will discuss the current state-of-the-art literature on clinical and preclinical data, and put forward potential cellular mechanisms and molecular pathways by which metformin ameliorates AKI/CKD.

show abstract

“…According to the guidelines of the American Diabetes Association and European Association for the Study of Diabetes the use of metformin is contraindicated if GFR (glomerular filtration rate) is <30 mL/min/1.73 m 2 . The dose of metformin should be adapted and optionally reduced depending on the renal function [14]. However, studies suggest that metformin can still be used with caution in patients with mild to moderate chronic kidney disease in conditions of monitoring the glomerular filtration rate (GFR) [15].…”

Section: 2mentioning

confidence: 99%

Metformin as a medicine decreasing cardiovascular risk in patients suffering from type 2 diabetes mellitus

Wieteska

Kaczyńska

Maj

et al. 2020

J Educ Health Sport

View full text Add to dashboard Cite

Almost half of deaths in Poland (approximately 49%) are caused by cardiovascular system diseases. It means that in 2018 it contributed to the death of over two hundred thousand people in our country. Myocardial infarction, stroke and heart failure are the most common of cardiovascular diseases (CVD). The main risk factor for progression of cardiovascular diseases is type 2 diabetes mellitus (T2D). It is estimated that almost 3 million people suffer from T2D in Poland. Metformin is a promising medicine that reduces cardiovascular risk in patients with T2D. It is currently used as the first line drug in patients suffering from T2D. The aim of the presented article is to review current research on the effectiveness of the metformin as a medicine that reduces cardiovascular risk in patients with T2D. Metformin is the oldest and most commonly used medicine that reduces the concentration of glucose in the peripheral blood in patients with T2D. Due to its very good safety profile, low cost and high effectiveness, metformin is used in the first-line treatment for T2D. Recent studies indicate its protective effect by vasodilation, reducing the size of myocardial infarction, inhibiting apoptosis of cardiomyocytes or reducing oxidative stress. Currently, metformin can be seen to have a great potential in the treatment of cardiovascular complications occurring in the course of T2D. Despite the fact that this medicine has been on the market for many years, the studies on its cardio protective effects have been carried out for a relatively short period of time. It is possible that the detailed understanding of all mechanisms of action of metformin will lead to future advances in the treatment of not only T2D, but also cardiovascular and cancer diseases.

show abstract

Changes in metformin use in chronic kidney disease

Cited by 20 publications

References 30 publications

Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways

Coreopsis tinctoria Nutt ameliorates high glucose-induced renal fibrosis and inflammation via the TGF-β1/SMADS/AMPK/NF-κB pathways

Metformin: A Candidate Drug for Renal Diseases

Metformin as a medicine decreasing cardiovascular risk in patients suffering from type 2 diabetes mellitus

Contact Info

Product

Resources

About